Login Register Cart 0
Generic placeholder image

Current Drug Targets

Editor-in-Chief

ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Vaccine for Targeted Therapy of Lung Cancer: Advances and Developments

Author(s): Suraj Kumar, Rishabha Malviya* and Prerna Uniyal

Volume 25, Issue 8, 2024

Published on: 06 May, 2024

Page: [526 - 529] Pages: 4

DOI: 10.2174/0113894501306103240426131249

Price: $65

Abstract

Considering that lung cancer is a leading global perpetrator, novel treatment approaches must be investigated. Due to the broad spectrum of lung cancer, conventional therapies including chemotherapy, radiotherapy, and surgeries, are not always effective and can have adverse consequences. The present study's overarching objective was to enhance the development of a personalized vaccine for targeted lung cancer therapy. Vaccination functions by eliciting a strong and targeted immune response defense by taking advantage of the specific antigens that are expressed by lung cancer cells. Crucial antigens associated with tumor cells have been identified with the recognition of the genetic and immunological circumstances of lung cancer in this review. The vaccine includes these antigens to prime the immune system, directing it toward recognizing and attacking cancerous cells. In this review, we have addressed the possible benefits of a targeted vaccine strategy, which include a reduction in off-target effects and an improvement in health outcomes for patients. These studies highlight the promise of a tailored vaccine in a novel way for the treatment of lung cancer. The integration of molecular profiling and immunological insights offers a rationale for the design and implementation of personalized vaccines. While challenges exist, the promise of improved treatment outcomes and reduced side effects positions targeted vaccine therapy as a compelling avenue for advancing lung cancer treatment.

« Previous Next »
Graphical Abstract

[1]
Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat 2020; 53: 100715.
[http://dx.doi.org/10.1016/j.drup.2020.100715] [PMID: 32679188]
[2]
Abbas S, Selamoglu Z, Sevindik M, et al. Enhanced heterologous immuno-boost (EHIB) covid-19 vaccines: A novel concept. Eurasian J Med Biol Sci 2023; 3(2): 67-79.
[3]
Nabavi Sf, Habtemariam S, Daglia M, Sureda A, Sobarzo E. Melatonin and respiratory diseases a review. Curr Top Med Chem 2017; 17(24): 1-22.
[4]
Selamoglu M. Importance of the cold chain logistics in the marketing process of aquatic products: An updated study. J Surv Fish Sci 2021; 25-9.
[http://dx.doi.org/10.18331/SFS2021.8.1.2]
[5]
Malvankar C, Kumar D. AXL kinase inhibitors-A prospective model for medicinal chemistry strategies in anticancer drug discovery. Biochim Biophys Acta Rev Cancer 2022; 1877(5): 188786.
[6]
Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer. Eur J Cancer 2015; 51(16): 2321-9.
[http://dx.doi.org/10.1016/j.ejca.2015.07.035] [PMID: 26283035]
[7]
Durgeau A, Virk Y, Gros G, et al. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018; 9(1): 5097.
[http://dx.doi.org/10.1038/s41467-018-07603-1] [PMID: 30504837]
[8]
Zara R, Rasul A, Sultana T, Jabeen F, Selamoglu Z. Identification of Macrolepiota procera extract as a novel G6PD inhibitor for the treatment of lung cancer. Saudi J Biol Sci 2022; 29(5): 3372-9.
[http://dx.doi.org/10.1016/j.sjbs.2022.02.018] [PMID: 35865797]
[9]
Selamoglu-Talas Z, Ozdemir I, Ciftci O, Cakir O. Propolis attenuates oxidative injury in brain and lung of nitric oxide synthase inhibited rats. J Pharm Care 2013; 45-50.
[10]
Talas ZS, Ozdemir I, Yilmaz I, Gok Y. Antioxidative effects of novel synthetic organoselenium compound in rat lung and kidney. Ecotoxicol Environ Saf 2009; 72(3): 916-21.
[http://dx.doi.org/10.1016/j.ecoenv.2007.11.012] [PMID: 18222543]
[11]
García-Pardo M, Gorria T, Malenica I, Corgnac S, Teixidó C, Mezquita L. Vaccine therapy in non-small cell lung cancer. Vaccines 2022; 10(5): 740.
[http://dx.doi.org/10.3390/vaccines10050740] [PMID: 35632496]
[12]
Rodriguez PC, Popa X, Martínez O, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non–small cell lung cancer patients. Clin Cancer Res 2016; 22(15): 3782-90.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0855] [PMID: 26927662]
[13]
Hirschowitz EA, Mullins A, Prajapati D, et al. Pilot study of 1650-G: A simplified cellular vaccine for lung cancer. J Thorac Oncol 2011; 6(1): 169-73.
[http://dx.doi.org/10.1097/JTO.0b013e3181fb5c22] [PMID: 21150468]
[14]
Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomized, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 59-68.
[http://dx.doi.org/10.1016/S1470-2045(13)70510-2] [PMID: 24331154]
[15]
Pujol JL, De Pas T, Rittmeyer A, et al. Safety and immunogenicity of the PRAME cancer immunotherapeutic in patients with resected non–small cell lung cancer: A phase I dose escalation study. J Thorac Oncol 2016; 11(12): 2208-17.
[http://dx.doi.org/10.1016/j.jtho.2016.08.120] [PMID: 27544054]
[16]
Ramlau R, Quoix E, Rolski J, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thorac Oncol 2008; 3(7): 735-44.
[http://dx.doi.org/10.1097/JTO.0b013e31817c6b4f] [PMID: 18594319]
[17]
Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EEW. The changing landscape of therapeutic cancer vaccines—novel platforms and neoantigen identification. Clin Cancer Res 2021; 27(3): 689-703.
[http://dx.doi.org/10.1158/1078-0432.CCR-20-0245] [PMID: 33122346]
[18]
Alfonso S, Valdés-Zayas A, Santiesteban ER, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2014; 20(14): 3660-71.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1674] [PMID: 24788102]
[19]
Somaiah N, Block MS, Kim JW, et al. First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1. Clin Cancer Res 2019; 25(19): 5808-17.
[http://dx.doi.org/10.1158/1078-0432.CCR-19-1025] [PMID: 31227504]
[20]
Donninger H, Li C, Eaton JW, Yaddanapudi K. Cancer vaccines: Promising therapeutics or an unattainable dream. Vaccines 2021; 9(6): 668.
[http://dx.doi.org/10.3390/vaccines9060668] [PMID: 34207062]
[21]
Addeo A, Friedlaender A, Giovannetti E, et al. A new generation of vaccines in the age of immunotherapy. Curr Oncol Rep 2021; 23(12): 137.
[http://dx.doi.org/10.1007/s11912-021-01130-x] [PMID: 34735649]
[22]
Gridelli C, Ciuleanu T, Domine M, et al. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: Final results of a randomised phase 2 clinical trial. Br J Cancer 2020; 122(10): 1461-6.
[http://dx.doi.org/10.1038/s41416-020-0785-y] [PMID: 32210365]
[23]
Voena C, Menotti M, Mastini C, et al. Efficacy of a cancer vaccine against ALK-rearranged lung tumors. Cancer Immunol Res 2015; 3(12): 1333-43.
[http://dx.doi.org/10.1158/2326-6066.CIR-15-0089] [PMID: 26419961]
[24]
First vaccine for treating ALK-positive lung cancer LUNGevity found. Available from: https://www.lungevity.org/blogs/developing-first-vaccine-for-treating-alk-positive-lung-cancer (accessed on 17 March 2022).
[25]
Sankar K, Nagrath S, Ramnath N. Immunotherapy for ALK-rearranged non-small cell lung cancer: Challenges inform promising approaches. Cancers 2021; 13(6): 1476.
[http://dx.doi.org/10.3390/cancers13061476] [PMID: 33806977]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy